Bone Protection in Patients with Breast and Lung Cancer

This patient case has been developed with the assistance of Dr. Alison Stopeck (Chief of the Division of Hematology/Oncology and Associate Director of Clinical and Translational Research, Stony Brook University Cancer Center, Stony Brook, NY, USA). This program was supported by Amgen USA.

The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient.

For full prescribing information including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Please note that products may have different product labeling according to geographical location. In the United States, full prescribing information is available from the US Food and Drug Administration (fda.gov).

All characters and events depicted in this patient case simulation are entirely fictitious. Any similarity to actual events or persons, living or dead, is purely coincidental. This activity is intended for healthcare professionals practicing in the USA. To proceed, please confirm that you are a healthcare professional practicing in the USA.

Modules

• Bone disease in metastatic triple-positive breast cancer